European Archives - Page 984 of 1136 - European Medical Journal

Janssen Receives CHMP Positive Opinion for STELARA® (Ustekinumab) Recommending Approval for the Treatment of Moderately to Severely Active Crohn’s Disease in the European Union

Belgium, September 16, 2016 – Janssen-Cilag International NV (“Janssen”) announced today that the Committee for Medicinal Products for Human Use (CHMP)…

EMJ

Scientists Mobilise Nanorobots to Fight Against Cancer

SWARMS of magneto-aerotactic bacteria equipped with covalently-bound drug-containing nanoliposomes have been administered into the bloodstream to…

EMJ

CRISPR Genome Editing Allows Blood Cells to Resist Sickle Cell Disease

INNOVATIVE CRISPR genome editing has been used to inhibit the pathological morphology of red blood cells caused by sickle cell disease, offering a new…

Glooko and Diasend Merge to Deliver the World’s Premier Diabetes Management Platform

To accelerate the overarching mission to make diabetes management easier, Glooko and Diasend announced to be merged into a unified company.

Acelity Launches PREVENA PLUS™ Incision Management System with Customizable Dressing for a Range of Complex Procedures

San Antonio, September 6, 2016 – Acelity, a global wound care and regenerative medicine company, today announced the expansion of its PREVENA™ Therapy…

EMJ

Blocking of CD47 Protein Found to be Effective Approach Against Skin Cancer

SCIENTISTS have found that blocking the signalling of the CD47 protein within specific populations of cancerous cells is an effective approach for…

EMJ

Adalimumab Improves Symptoms of Inflammatory Disease at First Stage of Clinical Trials

THE RESULTS of two Phase III clinical trials have shown that the tumour necrosis factor (TNF)-inhibitor adalimumab can improve the symptoms of…

Myocardial Nuclear Imaging: Minimizing the Dose – Preserving the Diagnostic Value

Vienna, September 6, 2016 – Cardiac scintigraphy plays an important role in the evaluation of patients with a suspicion or known coronary artery disease…

NICE Issues Draft Guidance for Xofigo® (Radium-223 Dichloride) for Treating Hormone-Relapsed Prostate Cancer with Bone Metastases in an Additional Group of Men

Newbury, September 2, 2016 – The National Institute for Health and Care Excellence (NICE) has recommended Xofigo® (radium-223 dichloride) in their draft…

ESMO Rewards Outstanding Oncologists

Switzerland, September 6, 2016 – The European Society for Medical Oncology (ESMO), the leading professional organisation for medical oncology, has…